--- title: "Psych News Alert: FDA Approves Deutetrabenazine for Treatment of Tardive Dyskinesia" description: Teva Pharmaceuticals Ltd. on Wednesday announced that the Food and Drug Administration has approved Austedo (deutetrabenazine) tablets f... image: https://alert.psychnews.org/hubfs/Imported_Blog_Media/FDA_NewLogo-Jun-24-2025-06-34-12-7974-PM.jpg --- 8/31/17 12:00 AM # FDA Approves Deutetrabenazine for Treatment of Tardive Dyskinesia ![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [ Psychiatric News Alert ](https://alert.psychnews.org/author/psychiatric-news-alert) Share: [facebook-f icon ](http://www.facebook.com/share.php?u=https://alert.psychnews.org/2017/08/fda-approves-deutetrabenazine-for.html) [linkedin-in icon ](http://www.linkedin.com/shareArticle?mini=true&url=https://alert.psychnews.org/2017/08/fda-approves-deutetrabenazine-for.html) [Twitter icon ](https://twitter.com/intent/tweet?url=https://alert.psychnews.org/2017/08/fda-approves-deutetrabenazine-for.html) [pinterest-p icon ](http://pinterest.com/pin/create/link/?url=https://alert.psychnews.org/2017/08/fda-approves-deutetrabenazine-for.html) [envelope icon ](mailto:?body=https://alert.psychnews.org/2017/08/fda-approves-deutetrabenazine-for.html) | ![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/FDA_NewLogo-Jun-24-2025-06-34-12-0313-PM.jpg?width=200&height=200&name=FDA_NewLogo-Jun-24-2025-06-34-12-0313-PM.jpg) | | | --- | --- | Teva Pharmaceuticals Ltd. on Wednesday [announced](http://www.businesswire.com/news/home/20170830006180/en/Teva-Announces-FDA-Approval-AUSTEDO%C2%AE-deutetrabenazine-Tablets) that the Food and Drug Administration has approved Austedo (deutetrabenazine) tablets for the treatment of adults with tardive dyskinesia (TD). Deutetrabenazine is a small molecule vesicular monoamine 2 transporter (VMAT2) inhibitor that has FDA approval for the treatment of chorea associated with Huntington’s disease. The [approval](https://www.austedo.com/hcp/pi) was based in part on the results of two 12-week, randomized, double-blind, placebo-controlled, multicenter trials, which compared changes in involuntary movements in 335 patients with TD who took deutetrabenazine or placebo. A total of 62% of the patients had concurrent diagnoses of schizophrenia/schizoaffective disorder, and 33% had a mood disorder; 86% were receiving concomitant antipsychotics.   For the first trial, 222 patients aged 21 to 81 were randomly assigned to deutetrabenazine (12 mg/day, 24 mg/day, 36 mg/day) or placebo. Two dosage levels—24 mg/day and 36 mg/day—were associated with statistically significant improvement in patients’ Abnormal Involuntary Movement Scale (AIMS) score, from baseline to week 12, compared with placebo. For the second trial, 113 patients aged 25 to 75 received daily doses of placebo or deutetrabenazine, starting at 12 mg/day, with titration up to 48 mg/day over a six-week period. This was followed by a six-week maintenance period at an average dose of 38.3 mg/day. From baseline to week 12, the AIMS total score decreased significantly in patients receiving deutetrabenazine compared with those receiving placebo.  “We are pleased to bring forward this second indication for Austedo to treat the underserved tardive dyskinesia population,” Michael Hayden, M.D., Ph.D., president of Global R&D and chief scientific officer at Teva, said in a Teva press release. “We believe physicians treating tardive dyskinesia will appreciate the therapy’s dosing flexibility and the ability to focus on directly treating the movement disorder and not disrupt the ongoing treatment for the underlying condition.” According to Teva, the most common adverse effects reported by patients taking Austedo were nasopharyngitis and insomnia.  For more information, see the *Psychiatric News PsychoPharm* article “[New Hope for Patients With Tardive Dyskinesia](http://psychnews.psychiatryonline.org/doi/full/10.1176/appi.pn.2016.pp12b5)” by Stanley N. Caroff, M.D. [schizophrenia](https://alert.psychnews.org/tag/schizophrenia), [tardive dyskinesia](https://alert.psychnews.org/tag/tardive-dyskinesia), [FDA](https://alert.psychnews.org/tag/fda), [antipsychotics](https://alert.psychnews.org/tag/antipsychotics), [schizoaffective disorder](https://alert.psychnews.org/tag/schizoaffective-disorder), [TD](https://alert.psychnews.org/tag/td) ## Related posts [![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/gingko_80252722-Jun-24-2025-09-32-13-9461-PM.jpg?height=200&name=gingko_80252722-Jun-24-2025-09-32-13-9461-PM.jpg) ](https://alert.psychnews.org/2011/08/ginkgo-biloba-may-counter-tardive.html) [schizophrenia](https://alert.psychnews.org/tag/schizophrenia), [tardive dyskinesia](https://alert.psychnews.org/tag/tardive-dyskinesia) ## [Ginkgo Biloba May Counter Tardive Dyskinesia](https://alert.psychnews.org/2011/08/ginkgo-biloba-may-counter-tardive.html) ![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [Psychiatric News Alert](https://alert.psychnews.org/author/psychiatric-news-alert) 8/1/11 12:00 AM Balazs Justin/Shutterstock A new Chinese study, reported in the Journal of Clinical Psychiatry, has... [ Read more ](https://alert.psychnews.org/2011/08/ginkgo-biloba-may-counter-tardive.html) [![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/man_window_iStock-523059734-Jun-24-2025-10-45-32-5786-PM.jpg?height=200&name=man_window_iStock-523059734-Jun-24-2025-10-45-32-5786-PM.jpg) ](https://alert.psychnews.org/2017/03/valbenazine-found-to-reduce-symptoms-of.html) [tardive dyskinesia](https://alert.psychnews.org/tag/tardive-dyskinesia), [FDA](https://alert.psychnews.org/tag/fda), [antipsychotics](https://alert.psychnews.org/tag/antipsychotics), [clinical trial](https://alert.psychnews.org/tag/clinical-trial) ## [Valbenazine Found to Reduce Symptoms of Tardive Dyskinesia in Patients With Schizophrenia](https://alert.psychnews.org/2017/03/valbenazine-found-to-reduce-symptoms-of.html) ![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [Psychiatric News Alert](https://alert.psychnews.org/author/psychiatric-news-alert) 3/21/17 12:00 AM Once-daily treatment with valbenazine (NBI-98854), a highly selective vesicular monoamine transport... [ Read more ](https://alert.psychnews.org/2017/03/valbenazine-found-to-reduce-symptoms-of.html) [![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/fda_2014_fw-Jun-24-2025-04-48-40-4090-PM.png?height=200&name=fda_2014_fw-Jun-24-2025-04-48-40-4090-PM.png) ](https://alert.psychnews.org/2017/04/fda-approves-first-medication-to-treat.html) [tardive dyskinesia](https://alert.psychnews.org/tag/tardive-dyskinesia), [FDA](https://alert.psychnews.org/tag/fda), [antipsychotics](https://alert.psychnews.org/tag/antipsychotics), [valbenazine](https://alert.psychnews.org/tag/valbenazine), [Ingrezza](https://alert.psychnews.org/tag/ingrezza), [Mitchell Mathis](https://alert.psychnews.org/tag/mitchell-mathis), [Stanley N. Caroff](https://alert.psychnews.org/tag/stanley-n-caroff), [VMAT2 inhibitor](https://alert.psychnews.org/tag/vmat2-inhibitor), [Neurocrine Biosciences](https://alert.psychnews.org/tag/neurocrine-biosciences) ## [FDA Approves First Medication to Treat Tardive Dyskinesia](https://alert.psychnews.org/2017/04/fda-approves-first-medication-to-treat.html) ![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [Psychiatric News Alert](https://alert.psychnews.org/author/psychiatric-news-alert) 4/12/17 12:00 AM The Food and Drug Administration on Tuesday announced it approved Ingrezza (valbenazine) capsules... [ Read more ](https://alert.psychnews.org/2017/04/fda-approves-first-medication-to-treat.html) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Psychiatric News Alert", "url" : "https://alert.psychnews.org/author/psychiatric-news-alert" }, "dateModified" : "2025-06-24T18:39:10.370Z", "datePublished" : "2017-08-31T04:00:00.000Z", "headline" : "Psych News Alert: FDA Approves Deutetrabenazine for Treatment of Tardive Dyskinesia", "image" : [ "https://alert.psychnews.org/hubfs/Imported_Blog_Media/FDA_NewLogo-Jun-24-2025-06-34-12-7974-PM.jpg" ], "mainEntityOfPage" : { "@id" : "https://alert.psychnews.org/2017/08/fda-approves-deutetrabenazine-for.html", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://alert.psychnews.org/hubfs/PN-Blue-Box.jpg" } } } ```